

Published in final edited form as:

Science. 2009 April 10; 324(5924): 261–265. doi:10.1126/science.1170944.

Glioma-Derived Mutations in *IDH1* Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 α

Shimin Zhao^{1,2}, Yan Lin^{1,*}, Wei Xu^{1,2,*}, Wenqing Jiang^{1,2,*}, Zhengyu Zha¹, Pu Wang^{1,2}, Wei Yu^{1,2}, Zhiqiang Li⁴, Lingling Gong⁵, Yingjie Peng⁶, Jianping Ding⁶, Qunying Lei^{1,3}, Kun-Liang Guan^{1,3,7,†}, and Yue Xiong^{1,2,8,†}

¹Molecular and Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, 130 Dong-An Road, Shanghai 200032, China.

²School of Life Sciences, Fudan University, 220 Han-Dan Road, Shanghai 200433, China.

³Department of Biological Chemistry, School of Medicine, Fudan University, 130 Dong-An Road, Shanghai 200032, China.

⁴Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.

⁵Department of Pathology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.

⁶State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China.

⁷Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.

⁸Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA.

Abstract

Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (*IDH1*) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived *IDH1* mutations impair the enzyme's affinity for its substrate and dominantly inhibit wild-type *IDH1* activity through the formation of catalytically inactive heterodimers. Forced expression of mutant *IDH1* in cultured cells reduces formation of the enzyme product, α -ketoglutarate (α -KG), and increases the levels of hypoxia-inducible factor subunit HIF-1 α , a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by α -KG. The rise in HIF-1 α levels was reversible by an α -KG derivative. HIF-1 α levels were higher in human gliomas harboring an *IDH1* mutation than in tumors without a mutation. Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Gliomas are the most common type of human brain tumors and can be classified based on clinical and pathological criteria into four grades. The grade IV glioma, commonly known as

[†]To whom correspondence should be addressed. kuguan@ucsd.edu (K.-L.G.); yxiong@email.unc.edu (Y.X.).

*These authors contributed equally to this work.

Supporting Online Material

www.sciencemag.org/cgi/content/full/324/5924/261/DC1

Figs. S1 to S4

Table S1

References

glioblastoma multiforme (GBM), has one of the worst prognoses among all types of human tumors and can develop either de novo (primary GBM) or through progression from low-grade tumors (secondary GBM). Although pathologically indistinguishable, primary and secondary GBM exhibit distinct patterns of cancer gene alterations (1). A recent cancer genome sequencing project revealed that the gene encoding *IDH1* is somatically mutated predominantly in secondary GBM (2). Three subsequent studies of targeted *IDH1* gene sequencing confirmed this finding, together identifying *IDH1* mutations in more than 70% of secondary GBM or low-grade gliomas but infrequently in primary GBM (about 5%) (3–5). Notably, all of the *IDH1* mutations identified to date produce a single amino acid substitution at Arg¹³² (R132) and no obvious inactivating (frame-shift or protein-truncation) mutations were found. This observation, together with the fact that the tumors do not show loss-of-heterozygosity (LOH), has led to speculation that R132 mutations lead to oncogenic activation of the enzyme.

IDH enzymes catalyze the oxidative decarboxylation of isocitrate (ICT) to produce α -KG. The human genome has five *IDH* genes coding for three distinct IDH enzymes whose activities are dependent on either nicotinamide adenine dinucleotide phosphate (NADP⁺-dependent IDH1 and IDH2) or nicotinamide adenine dinucleotide (NAD⁺-dependent IDH3). Both IDH2 and IDH3 enzymes are localized in the mitochondria and participate in the citric acid (TCA) cycle for energy production, whereas IDH1 is localized in the cytoplasm and peroxisomes (6). The R132 residue is conserved in all NADP⁺-dependent IDHs.

To explore the functional impact of the tumor-associated mutations at R132, we performed modeling studies based on the previously reported human cytosolic IDH1 crystal structure (7). Among all residues involved in binding with ICT, the side chain of R132 uniquely forms three hydrogen bonds with both the α - and β -carboxyl groups of the substrate ICT, whereas other residues involved in ICT binding form no more than two hydrogen bonds (Fig. 1A). Substitution of R132 with any one of the six amino acids observed in gliomas (His, Ser, Gly, Cys, Val, and Leu) would impair interactions of the enzyme with ICT both sterically and electrostatically. Representative modeling of H132, which corresponds to the most prevalent *IDH1* mutation in human gliomas, is shown in Fig. 1A. We determined the in vitro enzymatic activities of three tumor-derived IDH1 mutants, R132H, R132C and R132S, expressed in transformed human embryonic kidney (HEK) 293T cells and found that all three mutants have a greater than 80% reduction in activity as compared with the wild-type (WT) IDH1 (Fig. 1B). Analysis of recombinant IDH1 mutant proteins purified from *Escherichia coli* likewise displayed little activity in vitro compared with wild-type controls (Fig. 1B). Kinetic analyses of recombinant IDH1 proteins revealed that all three mutant IDH1s had a dramatically reduced affinity for ICT: The Michaelis constants (K_m s) of IDH1^{R132C}, IDH1^{R132S}, and IDH1^{R132H} for ICT were increased by factors of 60, 70, and 94, respectively (Fig. 1C). In contrast, the K_m for NADP⁺ and the maximum velocity (V_{max}) were not appreciably altered (Fig. 1C). Similarly, mutation of an arginine residue in pig mitochondrial IDH2 equivalent to R132 in human IDH1 caused a dramatic increase in K_m for isocitrate (by a factor of 165), with minimal effect on V_{max} (8). Because the normal cellular concentration of ICT is 20 to 30 μ M (9), which is lower than the K_m of the IDH1 mutants, the mutant enzymes are likely to have limited activity under physiological conditions. Together, these structural and biochemical analyses indicate that the tumor-associated *IDH1* mutations inactivate the enzyme.

Given that IDH1 normally functions as a homodimer, we hypothesized that the mutant IDH1 molecules in tumor cells form heterodimers with wild-type molecules and, in so doing, dominantly inhibit the activity of wild-type IDH1. To test this hypothesis, we coexpressed His-tagged wild-type and FLAG-tagged R132H mutant *IDH1* in *E. coli* and isolated the heterodimer by sequential affinity purification using first nickel resin and then FLAG beads.

Formation of either WT:WT homodimer or WT:R132H heterodimer was confirmed by gel filtration (fig. S1). As expected, the WT:WT homodimers were fully active and the R132H:R132H homodimers were nearly completely inactive (Fig. 2A). Notably, the WT:R132H heterodimer exhibited only 4% of the activity shown by the wild-type enzyme when assayed with limited ICT concentration (Fig. 2A). Normally, IDH1 can adopt at least three distinct conformations during catalysis: a quasi-open conformation when it is in a complex with NADP⁺, a quasi-closed conformation when it is in a complex with ICT, and a closed conformation when it is in a complex with both NADP⁺ and ICT (fig. S2A) (7). The two IDH1 subunits act in a cooperative manner and undergo conformational changes in a concerted way. Our modeling study suggests that the impairment in enzyme binding with ICT conferred by the R132 mutation in one subunit might also impair the binding of ICT to the second wild-type subunit. As a result, both subunits would be locked in an unliganded or quasi-open (NADP⁺-bound) conformation, thereby inhibiting catalytic activity (Fig. 2B for the close-up of the catalytic active site) (fig. S2, B and C). Consistent with this model, we found that the wild-type IDH1 exhibits a sigmoidal curve of cooperative binding to ICT, whereas the WT:R132H heterodimer displayed a hyperbolic curve with a much higher K_m (Fig. 2C), indicating that the heterodimer not only loses affinity but also cooperativity toward ICT.

We next investigated whether loss of IDH1 activity would alter cellular levels of α -KG, the product of IDH1 catalysis. We used RNA interference to down-regulate endogenous *IDH1* and determined the α -KG levels in U-87MG human glioblastoma cells. Two independent short hairpin RNAs (shRNAs) decreased *IDH1* mRNA by more than 75% and reduced cellular α -KG levels by up to 50% (fig. S3). Expression of the IDH1^{R132H} mutant at a level similar to the endogenous protein (fig. S4A) in the cytoplasm of U-87MG cells caused a dose-dependent reduction of α -KG levels (Fig. 2D) (fig. S4, A and B). Together, these data indicate that tumor-derived mutant IDH1 dominantly inhibits the wild-type IDH1 by forming a catalytically inactive heterodimer, resulting in a decrease of cellular α -KG.

Because α -KG is required by prolylhydroxylases (PHD), enzymes that hydroxylate and promote the degradation of hypoxia-inducible factor 1 α (HIF-1 α), we hypothesized that decreased IDH1 activity might stabilize HIF-1 α and increase its steady-state levels. We found that HIF-1 α protein levels in U-87MG cells were elevated in response to shRNA-mediated knockdown of *IDH1* (Fig. 3A). Conversely, overexpression of wild-type IDH1 reduced HIF-1 α protein levels in HeLa (fig. S5A) and U-87MG cells (Fig. 3B). Notably, overexpression of *IDH1*^{R132H} mutant increased HIF-1 α protein levels in U-87MG and HEK293T cells (Fig. 3B). These results suggest that IDH1 regulates HIF-1 α levels by controlling the level of α -KG. We tested this hypothesis by treating cells with octyl- α -KG, a cell-permeable derivative of α -KG that upon entering the cells is converted into α -KG after hydrolysis of the ester group (10). We found that octyl- α -KG suppressed the HIF-1 α induction caused by either *IDH1* knockdown in HeLa cells (fig. S5B) or overexpression of *IDH1*^{R132H} mutant in U-87MG cells (Fig. 3C). We therefore conclude that a reduction in IDH1 activity produces a reduction in α -KG levels that in turn can lead to stabilization of HIF-1 α .

We next determined whether inhibition of IDH1 enzyme activity leads to up-regulated expression of HIF-1 α target genes. HIF-1 α is a key component of HIF-1, a transcription factor that senses low cellular oxygen levels and that regulates the expression of genes implicated in glucose metabolism, angiogenesis, and other signaling pathways that are critical to tumor growth. Quantitative real-time fluorescence polymerase chain reaction (QPCR) of mRNAs corresponding to three well-established HIF-1 α target genes, glucose transporter 1 (*Glut1*), vascular endothelial growth factor (*VEGF*), and phosphoglycerate kinase (*PGK1*) showed that *IDH1* knockdown induced the expression of these HIF-1 α target

genes (fig. S6A). Moreover, expression of the *IDH1*^{R132H} mutant, but not wild-type *IDH1*, strongly induced HIF-1 α target gene expression (Fig. 4A). Oxalomalate, a competitive inhibitor of IDH1 (11) (fig. S6B), also induced expression of these HIF-1 α target genes (Fig. 4B).

Finally, we determined whether *IDH1* mutations correlate with elevated levels of HIF-1 α in human gliomas. In a collection of 26 glioma samples, we identified 8 tumors that contained the R132H mutation in one allele of *IDH1* (table S1) (fig. S7A). Using immunohistochemistry, we compared HIF-1 α expression in gliomas with and without *IDH1* mutations. We found that 8 tumors harboring the R132H mutation showed a statistically stronger HIF-1 α signal than did 12 tumors that did not harbor this mutation (Fig. 4C). In *IDH1* mutated tumors, 28.1 \pm 6.7% of the cells stained positive for HIF-1 α , whereas in tumors with wild-type *IDH1*, only 15.8 \pm 3.5% of the cells stained positive ($P < 0.001$) (Fig. 4C). *IDH1*-mutated gliomas also exhibited an increase in VEGF levels compared with gliomas without *IDH1* mutation of similar type and grade (fig. S7B).

In summary, we have shown that *IDH1* is likely to function as a tumor suppressor gene rather than as an oncogene. The glioma-associated mutations dominantly inhibit the activity of wild-type IDH1 through heterodimer formation (fig. S8). *IDH1* gene mutations in gliomas exhibit two unique features: the lack of LOH and the lack of apparent inactivating mutations such as frame-shift or truncations. Our findings help to explain both features, as dominant inhibition would eliminate the selection pressure to mutate or lose the remaining wild-type allele (LOH) and frame-shift or premature termination would likely generate IDH1 fragments unable to dimerize with and inhibit the wild-type IDH1 protein.

The link between *IDH1* and HIF-1 α highlights an emerging theme in which mutationally altered metabolic enzymes are thought to contribute to tumor growth by stimulating the HIF-1 α pathway and tumor angiogenesis. The genes encoding two TCA enzymes, fumarate hydratase (*FH*) and succinate dehydrogenase (*SDH*), have been found to sustain loss-of-function mutations in certain human tumors, which likewise correlate with an increase in HIF-1 α levels (10, 11). In addition to affecting PHD, an alteration in α -KG might contribute to tumorigenesis by affecting other dioxygenases that use α -KG as a substrate. IDH1 also catalyzes the production of NADPH; thus, it is possible that a reduction in NADPH levels resulting from IDH1 mutation contributes to tumorigenesis through effects on cell metabolism and growth. Several dozen anticancer agents directly targeting HIF-1 α are under development or being tested (12). Our finding that an α -KG derivative can reverse the induction of HIF-1 α levels in cultured cells expressing mutant *IDH1* suggests that drugs mimicking α -KG may merit exploration as a therapy for gliomas that harbor an *IDH1* mutation.

Supplementary Material


Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank members of the Fudan Molecular and Cell Biology Laboratory for valuable input; Y. Liu, X. Liu, and H. Zhu for assistance with histology; Z. Bao, L. Yang, Q. Shi, and G. Zhao for clinical samples; and S. Jackson for reading the manuscript. This work is supported by the 985 program from the Chinese Ministry of Education, State Key Development Programs of China (2009CB918401, 2006CB806700), National 863 Program of China (2006AA02A308), China NSF grants (30600112 and 30871255) and Shanghai Key Basic Research Projects (06JC14086, 07PJ14011, and 08JC1400900), and NIH grants (to K.-L.G. and Y.X.). Y. Xiong, K.-L. Guan, and S. Zhao are applying for a patent related to the work on permeable alpha-ketoglutarate.

References and Notes

1. Furnari FB, et al. *Genes Dev.* 2007; 21:2683. [PubMed: 17974913]
2. Parsons DW, et al. *Science.* 2008; 321:1807. [PubMed: 18772396]
3. Balss J, et al. *Acta Neuropathol.* 2008; 116:597. [PubMed: 18985363]
4. Bleeker FE, et al. *Hum. Mutat.* 2009; 30:7. [PubMed: 19117336]
5. Yan H, et al. *N. Engl. J. Med.* 2009; 360:765. [PubMed: 19228619]
6. Winkler BS, DeSantis N, Solomon F. *Exp. Eye Res.* 1986; 43:829. [PubMed: 3803464]
7. Xu X, et al. *J. Biol. Chem.* 2004; 279:33946. [PubMed: 15173171]
8. Soundar S, Danek BL, Colman RF. *J. Biol. Chem.* 2000; 275:5606. [PubMed: 10681542]
9. Albe KR, Butler MH, Wright BE. *J. Theor. Biol.* 1990; 143:163. [PubMed: 2200929]
10. MacKenzie ED, et al. *Mol. Cell. Biol.* 2007; 27:3282. [PubMed: 17325041]
11. Ingebretsen OC. *Biochim. Biophys. Acta.* 1976; 452:302. [PubMed: 12805]
12. Semenza GL. *Drug Discov. Today.* 2007; 12:853. [PubMed: 17933687]

**Fig. 1.**

Tumor-derived IDH1 mutants have reduced catalytic activity because of impaired isocitrate binding. **(A)** Structural modeling predicts that mutation of R132 in IDH1 would weaken hydrogen bonding of the enzyme to ICT. Shown is a view of the catalytic active site of human IDH1 bound with NADP⁺ (omitted for clarity), ICT (green), and Ca²⁺. The residues interacting with ICT from the adjacent subunit are labeled with an apostrophe. Hydrogen-bonding interactions are indicated with dashed lines. Simulated H132 mutation (cyan) is superimposed on R132. **(B)** Tumor-derived IDH1 mutants have reduced catalytic activity in vitro. Left, FLAG-tagged wild-type and mutant IDH1 were expressed in HEK293T cells, purified by immunoprecipitation and eluted by FLAG peptide; right, HIS-tagged wild-type and mutant IDH1 were expressed in *E. coli* and purified by nickel resin. Specific IDH1 activities for all proteins were measured in the presence of NADP⁺ (10 μM) and ICT (30 μM), with the presence of 2 mM Mn²⁺. Shown are mean values of triplicate experiments \pm SD. **(C)** Kinetic parameters of wild-type and mutant IDH1. Shown are mean values of duplicate experiments \pm SD.




Fig. 2. The R132H mutation dominantly inhibits IDH1 activity and reduces cellular levels of α -KG. (A) The WT:R132H heterodimer of IDH1 has low specific activity. The specific activities of WT:WT, R132H:R132H, and WT:R132H dimers were measured under conditions of NADP⁺ (10 μM), ICT (30 μM), and 2 mM MnCl₂. Activities were normalized by protein levels, and wild-type activity was arbitrarily set as 100%. Shown are mean values of triplicate experiments \pm SD. (B) A close-up view showing the conformational differences between the IDH1-NADP⁺ and IDH1-NADP⁺-ICT complexes at the active site. The enzyme adopts a quasi-open conformation in the IDH1-NADP⁺ complex (cyan) and a closed conformation in the IDH1-NADP⁺-ICT complex (yellow). The bound ICT and the side chains of several residues in IDH1 involved in ICT binding are shown. (C) The WT:R132H heterodimer loses cooperative binding to ICT. The activities of the WT:WT and WT:R132H enzymes were assayed with increasing concentrations of ICT in the presence of 100 μM

NADP⁺ and 2 mM Mn²⁺. Shown are mean values of duplicate assays \pm SD. The inset is an expanded view showing the IDH1 activities at lower isocitrate concentrations. **(D)** Cellular α -KG levels decrease with increasing IDH1^{R132H} expression. The upper panel is a Western blot showing expression levels of the transfected IDH1^{R132H} mutant in U-87MG cells. The α -KG level in cells transfected with empty vector was set as 100%, and this value was used to calculate the relative α -KG level in cells transfected with different amounts of IDH1^{R132H} mutant. Shown are mean values of triplicate assays \pm SD.




Fig. 3. α -KG mediates the HIF-1 α induction in cells with a decreased IDH1 activity (A) *IDH1* knockdown elevates HIF-1 α levels in U-87MG glioblastoma cells. IDH1 and HIF-1 α protein levels were determined by Western blotting from stable U-87MG cells transduced with empty retrovirus or retrovirus expressing different shRNAs silencing *IDH1*. (B) Ectopic expression of the *IDH1*^{R132H} mutant elevates HIF-1 α levels in U-87MG and HEK293T cells. The *IDH1*^{R132H} mutant was overexpressed in U-87MG or HEK293T cells, and protein levels were detected by Western blot. CoCl₂-treated cells (a mimetic of hypoxia) and cells overexpressing wild-type *IDH1* were also included as controls. (C) A cell-permeable α -KG derivative blocks HIF-1 α induction in cells expressing *IDH1*^{R132H}. The U-87MG cells were transfected with *IDH1*^{R132H}, and different concentrations of octyl- α -KG ester were added to each transfected cell for 4 hours. HIF-1 α protein levels were assayed by Western blot.




Fig. 4. IDH1 activity affects the levels of HIF-1 α and HIF-1 α target genes in gliomas and cultured cells. **(A)** Overexpression of the *IDH1*^{R132H} mutant in U-87MG cells stimulates expression of HIF-1 α target genes (*Glut1*, *VEGF*, and *PGK1*) as assayed by QPCR. Shown are mean values of triplicate assays \pm SD. **(B)** Inhibition of IDH1 by oxalomalate activates HIF-1 α target genes. U-87MG cells were either untreated (control), treated with 5 mM oxalomalate, an IDH1 inhibitor, or treated with CoCl₂, a hypoxia mimetic. HIF-1 α target gene mRNAs were determined. Shown are mean values of triplicate assays \pm SD. **(C)** Immunohistochemistry of HIF-1 α was carried out in 12 human gliomas with wild-type *IDH1* and 8 gliomas of similar grade harboring a mutated *IDH1* allele. Shown are side-by-side comparisons of four gliomas representing different types or grades. Scale bar, 40 μ M. Five fields (\sim 173 μ m² each) were randomly selected from each sample for quantification of HIF-1 α -positive staining area. Statistical analysis was performed using seven *IDH1* wild-type and seven *IDH1*-mutated gliomas.